This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ICAD Reports Third Quarter Financial Results

Use of Non-GAAP Financial Measures

In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's web site at www.icadmed.com.

Conference Call

iCAD management will host an investment community conference call beginning at 10:00 a.m. Eastern time on Thursday, October 27, 2011 to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-299-0148 (domestic) or 617-801-9711 (international) and entering passcode 12967438. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

A replay of the conference call will be accessible two hours after its completion through November 1, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 74124094. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent ® eBx™ electronic brachytherapy system. Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for the treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov .

   
iCAD, INC. AND SUBSIDIARY
 
Consolidated Balance Sheets
(Unaudited)
(In thousands except for share data)
 
September 30, December 31,

Assets

2011

2010

 
Current assets:
Cash and cash equivalents $ 5,288 $ 16,269
Trade accounts receivable, net of allowance for doubtful
accounts of $50 in 2011 and 2010 5,656 3,389
Inventory, net 2,132 3,489
Prepaid expenses and other current assets 576 581
Total current assets 13,652 23,728
 
 
Property and equipment, net of accumulated depreciation
and amortization of $2,600 in 2011 and $2,852 in 2010 2,118 2,774
Other assets 604 675
Intangible assets, net of accumulated amortization
of $8,317 in 2011 and $6,746 in 2010 17,584 21,165
Goodwill 20,907 45,689
Total assets $ 54,865 $ 94,031
 

Liabilities and Stockholders' Equity

Current liabilities:
Accounts payable $ 2,407 $ 2,500
Accrued and other expenses 4,518 5,902
Deferred revenue 5,702 4,906
Total current liabilities 12,627 13,308
 
Contingent consideration 0 5,000
Deferred revenue, long-term portion 1,628 961
Other long-term liabilities 1,000 1,552
Total liabilities 15,255 20,821
 
 
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares;
none issued. - -
Common stock, $ .01 par value: authorized 85,000,000
shares; issued 54,751,176 in 2011 and 54,383,747 in 2010;
outstanding 54,683,300 in 2011 and 54,315,871 in 2010 547 544
Additional paid-in capital 163,775 163,101
Accumulated deficit (123,762) (89,485)
Treasury stock at cost (67,876 shares) (950) (950)
Total stockholders' equity 39,610 73,210
 
Total liabilities and stockholders' equity $ 54,865 $ 94,031
 
       
iCAD, INC. AND SUBSIDIARY
Consolidated Statements of Operations
(Unaudited)
(In thousands except for per share data)
 
Three Months Ended September 30, Nine Months Ended September 30,
2011 2010 2011 2010
Revenue:
Products $ 5,754 $ 4,059 $ 15,463 $ 13,987
Service and supplies 2,298 1,527 6,579 4,217
Total revenue 8,052 5,586 22,042 18,204
 
Cost of revenue:
Products 1,280 544 3,627 1,769
Service and supplies 650 587 2,191 1,792
Amortization of acquired intangibles 233 - 700 -
Total cost of revenue 2,163 1,131 6,518 3,561
       
Gross profit 5,889 4,455 15,524 14,643
 
Operating expenses:
Engineering and product development 2,630 1,715 8,709 4,796
Marketing and sales 3,108 2,347 10,780 7,363
General and administrative 2,147 1,805 8,363 6,131
Contingent consideration (3,800) 0 (4,900) 0
Goodwill Impairment 26,750 0 26,750 0
Total operating expenses 30,835 5,867 49,702 18,290
       
Loss from operations (24,946) (1,412) (34,178) (3,647)
 
Gain on sale of patent - - - 275
Interest (expense) income - net (37) 19 (99) 58
Net loss $ (24,983) $ (1,393) $ (34,277) $ (3,314)
 
Net loss per share:
Basic and diluted $ (0.46) $ (0.03) $ (0.63) $ (0.07)
 
Weighted average number of shares used in
computing loss per share:
Basic and diluted 54,681 45,922 54,533 45,782
 

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO COMPARABLE GAAP MEASURES

(Unaudited, in thousands, except per share amounts)

4 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs